WILMINGTON, DE — New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers significant reductions in LDL cholesterol (LDL-C) when combined with standard-of-care statin therapy. The findings, presented at the American College of Cardiology’s Annual Scientific Session & Expo and published in JACC, underscore the drug’s potential as a breakthrough treatment for patients struggling to meet LDL-C targets.
At 12 weeks, AZD0780 30mg taken once daily reduced LDL-C levels by 50.7% and enabled 84% of participants to achieve guideline-recommended LDL-C levels, compared to just 13% of those on standard therapy alone. This efficacy was consistent across patient groups regardless of statin intensity.
Dr. Michael J. Koren, MD, Principal Investigator for PURSUIT, emphasized the importance of the results. “These findings demonstrate the potential of AZD0780 to offer a much-needed, convenient oral treatment option for patients who remain at risk for serious cardiovascular events, despite current therapies.”
The trial addresses a critical gap in cholesterol management, as over 70% of patients worldwide fail to meet LDL-C targets, increasing their risk of cardiovascular diseases such as heart attack and stroke.
Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, highlighted the drug’s convenience and impact, stating, “AZD0780 has the potential to be a game changer, offering an innovative solution for patients whose cholesterol levels remain unmanageable with standard therapies.”
The treatment was well tolerated, with comparable adverse events between the drug and placebo groups, supporting its potential as a safe alternative for long-term use.
These results build on earlier Phase I trial data and reinforce AstraZeneca’s commitment to advancing treatment options within cardiovascular, renal, and metabolic diseases, potentially setting a new standard in cholesterol management.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.